A patient who has been on alendronate (Fosamax) for two years now has a bone mineral density T‑score of –2.7 with no fractures; what should be the next step in management?

Continue Alendronate for at Least 3 More Years

This patient with a T-score of –2.7 after 2 years of alendronate remains at high risk for fractures and should continue bisphosphonate therapy; reassessment for a potential drug holiday is only appropriate after 3–5 years of total treatment. 1

Rationale for Continued Treatment

The Endocrine Society guideline explicitly recommends reassessing fracture risk after 3 to 5 years of bisphosphonate therapy, not after 2 years. 1 A bisphosphonate holiday is considered only for patients who are at low-to-moderate fracture risk after this duration. 1

Why This Patient Remains High Risk

• T-score of –2.7 defines osteoporosis (T-score ≤ –2.5), placing the patient in a category that requires ongoing antiresorptive therapy. 1
• The absence of fractures is reassuring but does not eliminate high fracture risk when bone density remains in the osteoporotic range. 1
• Alendronate produces mean lumbar spine BMD increases of approximately 7% over 2 years, 1 so this patient's current T-score of –2.7 likely reflects improvement from an even lower baseline—indicating persistent skeletal fragility.

Treatment Plan Algorithm

Step 1: Continue Alendronate 70 mg Weekly

• Maintain the current regimen of alendronate 70 mg once weekly (or 10 mg daily if that was the original formulation). 1, 2
• Ensure the patient takes the medication on an empty stomach with 6–8 oz of plain water, followed by at least 30 minutes of upright posture before any food or other medications. 3

Step 2: Optimize Calcium and Vitamin D

• Confirm total calcium intake of approximately 1200 mg daily from diet plus supplements. 1, 2
• Prescribe vitamin D supplementation of 800–1000 IU daily and verify serum 25-OH-D levels are ≥ 30 ng/mL to prevent hypocalcemia. 3

Step 3: Reassess at Year 3 or 5

• Repeat DXA scan at 3 years (total treatment duration) if the patient is on annual intravenous zoledronic acid, or at 5 years if on oral alendronate. 1
• At that time, evaluate whether the patient has transitioned to low-to-moderate fracture risk based on:
  • BMD improvement (ideally T-score > –2.5)
  • No new fractures
  • No other clinical risk factors (e.g., age > 75, glucocorticoid use, history of falls)

Step 4: Consider a Drug Holiday Only If Low-to-Moderate Risk

• If the patient meets low-to-moderate risk criteria after 3–5 years, a bisphosphonate holiday of up to 5 years may be initiated. 1
• During the holiday, reassess fracture risk every 2–4 years with repeat DXA and consider restarting therapy if BMD declines significantly, a fracture occurs, or clinical risk status changes. 1
• If the patient remains at high risk (T-score still ≤ –2.5, multiple vertebral fractures, or age > 75), continue alendronate beyond 5 years to maintain fracture protection. 1

Monitoring During Continued Therapy

• BMD monitoring: Repeat DXA at the spine and hip every 1–3 years to assess treatment response. 1
  • Expected BMD increases with alendronate are approximately 7% at the lumbar spine and 5% at the total hip over 2 years. 1
  • Stable or increasing BMD indicates a good response; a decline exceeding the least significant change (4–5%) warrants investigation for nonadherence or secondary causes of bone loss. 1
• Bone turnover markers (optional): Serum CTX or P1NP can identify poor response or nonadherence earlier than BMD changes. 1

Safety Considerations

• Atypical femoral fractures (AFFs): Risk increases with bisphosphonate duration beyond 5 years (approximately 50 per 100,000 person-years after 8+ years), but this risk remains far lower than the risk of osteoporotic hip fractures that alendronate prevents. 1
• Upper GI adverse events: Alendronate is generally well tolerated when taken correctly; ensure the patient adheres to dosing instructions to minimize esophageal irritation. 2, 4
• Osteonecrosis of the jaw (ONJ): Incidence is extremely low (≈ 0–1% annually) in osteoporosis patients on standard-dose alendronate. 5 Maintain good oral hygiene and complete any invasive dental procedures before continuing therapy. 5

Common Pitfall to Avoid

Do not initiate a bisphosphonate holiday at 2 years. The evidence supporting drug holidays applies only after 3–5 years of therapy, and only in patients who have transitioned to low-to-moderate fracture risk. 1 Premature discontinuation in a patient with a T-score of –2.7 would leave them vulnerable to rapid bone loss and increased fracture risk. 6

Alternative Agents (If Alendronate Is Not Tolerated)

• Denosumab 60 mg subcutaneously every 6 months is an alternative for patients who cannot tolerate oral bisphosphonates or have contraindications (e.g., esophageal disease, creatinine clearance < 35 mL/min). 1
  • Critical: Denosumab must be given precisely every 6 months; delays produce a dangerous rebound increase in bone turnover and fracture risk. 1, 7
• Zoledronic acid 5 mg intravenously annually is another option for patients with GI intolerance or poor adherence to oral therapy. 1